Tianchen Bio develops next-generation large‑molecule antibodies targeting unmet needs in autoimmune diseases. Its R&D pipeline concentrates on autoimmune indications with multiple candidates progressing steadily. The company leverages three technology platforms: antibody discovery, antibody engineering, and process development. Tianchen intends to continue advancing and expanding its pipeline to deliver clinical benefits to patients. Recently it completed a Series B financing of over RMB 100 million to support its programs. Proceeds will be used for clinical advancement, industrialization preparation, and to support internationalization efforts.

Total raised

$14M

Funding rounds

1

Latest round

Series B

Latest activity

Oct 2023